Medpace Holdings, Inc. (MEDP)
D
Pipeline Grade
Financial Position (from SEC Filings)
$652.7M
Cash & Equivalents
$151.8M
Quarterly Burn Rate
$15,372M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-30 | Phase2 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04798430 | Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction | PHASE3 | Enrolling By Invitation | 2,000 |
| NCT07197580 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC | PHASE3 | Recruiting | 40 |
| NCT04329728 | The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | PHASE2 | Recruiting | 144 |
| NCT05986851 | Azeliragon in MGMT Unmethylated Glioblastoma | PHASE2 | Active Not Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.